112 related articles for article (PubMed ID: 26658589)
1. Alterations in the levels of plasma amino acids in polycystic ovary syndrome--A pilot study.
Unni SN; Lakshman LR; Vaidyanathan K; Subhakumari KN; Menon NL
Indian J Med Res; 2015 Nov; 142(5):549-54. PubMed ID: 26658589
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study.
Atiomo W; Daykin CA
Mol Hum Reprod; 2012 Nov; 18(11):546-53. PubMed ID: 22809877
[TBL] [Abstract][Full Text] [Related]
3. Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances.
Ye Z; Zhang C; Wang S; Zhang Y; Li R; Zhao Y; Qiao J
Reprod Biomed Online; 2022 Apr; 44(4):737-746. PubMed ID: 35131170
[TBL] [Abstract][Full Text] [Related]
4. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients.
Sun L; Hu W; Liu Q; Hao Q; Sun B; Zhang Q; Mao S; Qiao J; Yan X
J Proteome Res; 2012 May; 11(5):2937-46. PubMed ID: 22428626
[TBL] [Abstract][Full Text] [Related]
5. Detailed characterisation of circulatory nitric oxide and free radical indices--is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome?
Willis GR; Udiawar M; Evans WD; Blundell HL; James PE; Rees DA
BJOG; 2014 Dec; 121(13):1596-603. PubMed ID: 24816317
[TBL] [Abstract][Full Text] [Related]
6. NMR Metabolomics Show Evidence for Mitochondrial Oxidative Stress in a Mouse Model of Polycystic Ovary Syndrome.
Selen ES; Bolandnazar Z; Tonelli M; Bütz DE; Haviland JA; Porter WP; Assadi-Porter FM
J Proteome Res; 2015 Aug; 14(8):3284-91. PubMed ID: 26076986
[TBL] [Abstract][Full Text] [Related]
7. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolomics of Indian women with polycystic ovary syndrome using
RoyChoudhury S; Mishra BP; Khan T; Chattopadhayay R; Lodh I; Datta Ray C; Bose G; Sarkar HS; Srivastava S; Joshi MV; Chakravarty B; Chaudhury K
Mol Biosyst; 2016 Oct; 12(11):3407-3416. PubMed ID: 27714060
[TBL] [Abstract][Full Text] [Related]
9. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome.
Battaglia C; Mancini F; Cianciosi A; Busacchi P; Facchinetti F; Marchesini GR; Marzocchi R; de Aloysio D
Obstet Gynecol; 2008 Feb; 111(2 Pt 1):385-95. PubMed ID: 18238977
[TBL] [Abstract][Full Text] [Related]
10. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome.
Choi JH; Rhee EJ; Kim KH; Woo HY; Lee WY; Sung KC
Eur J Endocrinol; 2011 Nov; 165(5):789-96. PubMed ID: 21865408
[TBL] [Abstract][Full Text] [Related]
11. Association of heme oxygenase-1 with the risk of polycystic ovary syndrome in non-obese women.
Gao H; Meng J; Xing H; Nie S; Xu M; Zhang S; Jin Y; Sun T; Huang H; Zhang H; Wang D; Liu L
Hum Reprod; 2014 May; 29(5):1058-66. PubMed ID: 24585089
[TBL] [Abstract][Full Text] [Related]
12. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
13. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
14. Changes in sexual function among women with polycystic ovary syndrome: a pilot study.
Ferraresi SR; Lara LA; Reis RM; Rosa e Silva AC
J Sex Med; 2013 Feb; 10(2):467-73. PubMed ID: 23210985
[TBL] [Abstract][Full Text] [Related]
15. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study.
Pontikis C; Yavropoulou MP; Toulis KA; Kotsa K; Kazakos K; Papazisi A; Gotzamani-Psarakou A; Yovos JG
J Womens Health (Larchmt); 2011 Jun; 20(6):971-6. PubMed ID: 21671782
[TBL] [Abstract][Full Text] [Related]
16. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Panidis D; Farmakiotis D; Rousso D; Katsikis I; Delkos D; Piouka A; Gerou S; Diamanti-Kandarakis E
Eur J Intern Med; 2008 Oct; 19(6):406-12. PubMed ID: 18848173
[TBL] [Abstract][Full Text] [Related]
17. Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered.
Torun AN; Vural M; Cece H; Camuzcuoglu H; Toy H; Aksoy N
Gynecol Endocrinol; 2011 Dec; 27(12):988-92. PubMed ID: 21557696
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone.
Armanini D; Bordin L; Donà G; Sabbadin C; Bakdounes L; Ragazzi E; Giorgino FL; Fiore C
Steroids; 2012 May; 77(6):655-8. PubMed ID: 22387621
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
20. Association between arginase-containing platelet-derived microparticles and altered plasma arginine metabolism in polycystic ovary syndrome.
Kyselova A; Hinrichsmeyer H; Zukunft S; Mann AW; Dornauf I; Fleming I; Randriamboavonjy V
Metabolism; 2019 Jan; 90():16-19. PubMed ID: 30367832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
